Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
Merck
Boehringer Ingelheim
Colorcon

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Litigation Details for CARIK v. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES (D.C. 2012)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

CARIK v. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES (D.C. 2012)

Docket   Start Trial Date Filed 2012-02-17
Court District Court, District of Columbia Date Terminated 2013-11-27
Cause 28:2201fs Declaratory Judgment (Food Security Act) Assigned To Beryl Alaine Howell
Jury Demand None Referred To
Parties ADAM DIBLE; ALL PLAINTIFFS; CAROL E. EMERSON; FRANCIS S. COLLINS; GEORGE DEMKO; JAMES BEADNELL; JANE DOE; JENNIFER LACOGNATA; JOHN DOE; JOSEPH M. CARIK; JOY BEADNELL; KATHLEEN SEBELIUS; LAURA WINCHESTER; MARGARET A. HAMBURG; MICHAEL A. MASULA; MICHAEL GNIDOVEC; MOUNT SINAI SCHOOL OF MEDICINE; THOMAS JAMES OLSZEWSKI; THOMAS STANZIANO; UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UNITED STATES NATIONAL INSTITUTES OF HEALTH
Patents 5,356,804
Attorneys Andrew E. Clark; Charles Allen Black , Jr.; David Ludwig; Douglas Harry Hallward-Driemeier; Lauren Hash Bell; Thomas Mansfield Dunlap; W. Clifton Holmes
Firms Dunlap Bennett & Ludwig Pllc; Ludwig & Robinson Pllc; Ropes & Gray LLP; The Law Office of C. Allen Black, Jr.; U.S. DEPARTMENT OF JUSTICE, Consumer Protection Branch Civil Division
Link to Docket External link to docket
Biologic Drugs cited in CARIK v. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES
The biologic drug covered by the patent cited in this case is   Start Trial .

Details for CARIK v. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES (D.C. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-02-17 1 /lt. Sinai licenses the Fabrazyme patent (U.S. Patent No. 5,356,804) to Genzyme to benefit U.S. citizens…ofU.S. Patent No. 13 Case 1:12-cV-00272-BAH Document 1 Filed 02/17/12 Page 14 of 90 5,356,804, an invention…invalidation or lack of enforceability of U.S. Patent No. 5,356,804 covering use ofFabrazyme. 1\/1t. Sinai is…Disease 225. l\/lt. Sinai was granted U.S. Patent No, 5,356,804 to a method of producing agalsidase beta…Bayh-Dole Act 226. l\/lt, Sinai licensed U.S. Patent No. 5,356,804 for the manufacture of agalsidase beta ( External link to document
2012-04-23 19 Attachments: # 1 Exhibit Patent Assignment Details, U.S. Patent No. 5,356,804, # 2 Exhibit Confirmatory…Confirmatory License, U.S. Patent No. 5,356,804, # 3 Exhibit GAO Report (July 2009), Information on the Governments External link to document
2013-11-27 28 use its march-in authority on U.S. Patent No. 5,356,804,” the patent for Fabrazyme. See Defs.’ Notice …its Bayh-Dole March-In Authority on U.S. Patent No. 5,356,804”) at 1, ECF No. 24-1. The NIH declined to…an allegedly invalid patent, independent of any harm that the use of the patent caused, see id. at 15…prescribed dose of Fabrazyme, NIH required [the patent owner, Mount Sinai,] to report on the status of… 5 Specifically, the NIH found that granting “patent use rights to a third party will not increase the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
Merck
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.